echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Zhejiang notified that Dawnrays Pharmaceuticals refused to supply after the centralized procurement. Why did similar incidents happen repeatedly?

    Zhejiang notified that Dawnrays Pharmaceuticals refused to supply after the centralized procurement. Why did similar incidents happen repeatedly?

    • Last Update: 2021-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Reporter | Jin Miao

    On April 14, the Zhejiang Pharmaceutical Equipment Procurement Center issued the "Notice on the Results of the Volume Procurement of Cefmetazole Injection Forms", which showed that in the first batch of volume procurement work in Zhejiang Province formally implemented on March 15th, Suzhou East The "Cefmetazole Sodium for Injection" (powder injection, specification 1.
    0g) declared by Rui Pharmaceutical Co.
    , Ltd.
    was selected.
    The company refused to fulfill the obligation of the selection, and has not completed the signing of the purchase and sales agreement and the resume distribution relationship, which affected the normal implementation of the selection results
    .

    The Zhejiang Pharmaceutical Equipment Purchasing Center decided to purchase the cefmetazole injection dosage form in quantity, and treat it as a non-selected product.
    All medical and health institutions temporarily purchase according to the original method; each medical and health institution does not comply with the requirements due to Suzhou Dawnrays Pharmaceutical Co.
    , Ltd.
    If the performance of obligations causes losses or other civil rights are violated, rights can be protected in accordance with the law; drug procurement is related to the health of the masses.
    In order to ensure normal medical order and clinical use of drugs, medical and health institutions should choose carefully, and try to avoid choosing breaches of contract, dishonesty, etc.
    The company purchases products
    .

    Suzhou Dawnrays Pharmaceutical Co.
    , Ltd.
    is a subsidiary of Dawnrays Pharmaceuticals (Holdings) Co.
    , Ltd.
    The latter covers the entire industry chain of cephalosporin antibiotics APIs, intermediates, and powder injections.
    It was listed on the main board of the Hong Kong Stock Exchange in 2003
    .

           Since the beginning of volume procurement at the end of 2018, the supply of selected products has been out of supply due to production capacity and price factors
    .


    In 2019, after Bristol-Myers Squibb’s Fosinopril Sodium Tablets followed up the "4+7" price in Hebei Province, due to insufficient supply, they could only be supplemented by the non-winning company Huahai Pharmaceutical


           In 2020, the Yunnan Provincial Medical Insurance Bureau released 8 items that were abnormally supplied by selected enterprises in Yunnan for the centralized procurement of national drugs, involving Suzhou Dongrui, Xing'an Pharmaceutical, Changzhou Siyao, Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical, and Sinopharm Rongsheng Pharmaceutical , Hanhui Pharmaceutical, Guangzhou Baiyunshan Tianxin Pharmaceutical, Hunan Warner Pharmaceutical Factory's Entecavir, Atorvastatin Calcium, Amlodipine Besylate
    .


    During this cut-off, nearly one-third of the 25 varieties that were expanded by centralized procurement were cut-off


           8:00 Jianwen previously reported that after the third batch of purchases by a certain southern hospital, it encountered a situation where sodium bicarbonate tablets and celecoxib tablets had not been delivered 5 months after the implementation
    .

           When the “floor price” of centralized procurement occurs frequently, and some winning bid prices are even difficult to cover costs, preventing companies from malicious bidding and reducing supply cuts caused by the difficulty of winning bid prices to cover costs have become key issues of concern to medical insurance departments in various regions
    .

           In August 2020, the National Medical Insurance Administration issued the "Guiding Opinions of the National Medical Security Administration on the Establishment of a Medical Price and Recruitment Credit Evaluation System" (abbreviated as the "Guiding Opinions"), which clearly proposes the establishment of a credit evaluation catalogue list to deal with improper price behaviors.
    , Disrupting the order of centralized procurement, maliciously violating contractual agreements and other behaviors that are contrary to the city's credit, shall be included in the scope of medical prices and credit evaluation of recruitment and procurement
    .

           Since then, the "Guiding Opinions" have been implemented in various provinces and cities
    .


    Taking Guizhou Province as an example, in November 2020, the Guizhou Provincial Public Resources Trading Center announced that 11 pharmaceutical companies, 23 drugs, and 27 product specifications.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.